Pharmaceutical

AbbVie signs agreement to acquire Aliada for $1.4bn

AbbVie has entered a definitive agreement to acquire all outstanding equity of Aliada Therapeutics in a deal valued at $1.4bn in cash.

Oct 30, 2024 - 04:00
AbbVie signs agreement to acquire Aliada for $1.4bn
AbbVie has entered a definitive agreement to acquire all outstanding equity of Aliada Therapeutics in a deal valued at $1.4bn in cash.
Read the original article

Tags:

Previous Article

South Korean pricing reform suggests more flexible drug reimbursement negotiations

Next Article

Transforming pharmaceutical R&D: the impact of digital technologies on drug disc...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Rocket Pharmaceuticals’ RP-A601 receives FDA designations

Rocket Pharmaceuticals’ RP-A601 receives FDA designations

Jun 9, 2023

Coherus allies with Mark Cuban to challenge AbbVie for Humira biosimilar

Coherus allies with Mark Cuban to challenge AbbVie for ...

Jun 3, 2023

STAT+: Change Healthcare cyberattack outage could persist for weeks, UnitedHealth Group executive suggests

STAT+: Change Healthcare cyberattack outage could persi...

Feb 29, 2024